Jan-Henrik Terwey

Analysis of <i>KRAS</i> / <i>NRAS</i> Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Kelly S. Oliner, Timothy Price et al. · Clinical Cancer Research · 2015 · 185 citations · Full text

Medicine, Oncology, Pharmacology +17

Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials

Marc Peeters, George Kafatos, Aliki Taylor et al. · European Journal of Cancer · 2015 · 162 citations

Medicine, Molecular Medicine, Oncology +14

Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer

Jean‐Yves Douillard, Salvatore Siena, Marc Peeters et al. · European Journal of Cancer · 2015 · 82 citations · Full text

Medicine, Oncology, Molecular Oncology +14

First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) <i>RAS</i> metastatic colorectal carcinoma (mCRC): Tumor response outcomes beyond RECIST.

Fernando Rivera, Meinolf Karthaus, J. Randolph Hecht et al. · Journal of Clinical Oncology · 2015 · 17 citations

Medicine, Oncology, Pharmacotherapy +15

Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study

Jean‐Loup Mouysset, Beata Freier, Joan van den Bosch et al. · Cancer Management and Research · 2016 · 16 citations · Full text

Medicine, Hematology, Oncology +17